Biosimilar

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss leadership in eye care with guest Jack T. Holladay, MD, MSEE, FACS.

The Mark Cuban Cost Plus Drug Company launched in January 2022 to a flurry of promises, curiosity, and a certain guarded optimism among experts regarding its potential to lower medication prices for patients.

In this edition, difficult-to-treat psoriatic arthritis 'not all about the therapies', Samsung biosimilar comparable to etanercept and more.

Boehringer Ingelheim has partnered with Quallent Pharmaceuticals to expand access to its Humira biosimilar citrate-free adalimumab-adbm in the United States, according to a company press release.

Patients with psoriatic arthritis demonstrated similar disease activity outcomes and drug persistence after long-term treatment with either etanercept or its biosimilar SB4, according to data published in Arthritis Care & Research.

The FDA has approved a citrate-free, high-concentration formulation of the interchangeable adalimumab biosimilar Cyltezo to treat multiple chronic inflammatory diseases, according to the manufacturer.

The FDA has approved trastuzumab-strf as a biosimilar to trastuzumab for the treatment of certain patients with HER2-overexpressing malignancies, according to a press release from the agent’s manufacturer.

A biosimilar for golimumab has demonstrated therapeutic equivalence in rheumatoid arthritis, with no clinically meaningful safety differences, according to a press release from the manufacturer.

The FDA has approved Selarsdi as a biosimilar to Stelara for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis, Teva Pharmaceuticals and Alvotech announced in a press release.

In a Healio video exclusive, Edward V. Loftus Jr., MD, noted that although some concerns remain for switching patients between interchangeable biosimilars, data has continued to show acceptable outcomes as well as “increased access.”